Biofrontera Upgraded to Buy as EPS Estimates Rise 300%
Biofrontera Inc. was upgraded to a Buy rating after analysts hiked fiscal 2025 EPS estimates by 300% over the past three months. The consensus now forecasts a -$1.27 per share loss for 2025, reflecting strong upward revisions that may drive near-term share gains.
1. Buy Rating Upgrade
Biofrontera Inc. received a Buy rating upgrade based on an improving earnings outlook, positioning the stock in the top 20% of rated stocks for estimate revisions.
2. EPS Estimate Revisions
Over the past three months, sell-side estimates for fiscal 2025 EPS have risen by 300%, driving the consensus forecast to a -$1.27 loss per share.
3. Potential Share Impact
Rising earnings forecasts often attract institutional buying, which could translate into upward pressure on Biofrontera’s share price in the near term.
Related News
SATS
SpaceX Sets $1.75 Trillion Valuation, Values EchoStar Shares at $42.40 in IPO Filing
SATS•
BLTE
Belite Bio Begins FDA NDA Rolling Submission, Q1 Loss Widens on $15.7M R&D
BLTE•
WGRX
Wellgistics Health Approves 1-for-50 Reverse Split to Raise Share Price
WGRX•
VBCH
Vanguard’s BondBuilder Suite Amasses $242M in Two Months, Fuels $70B ETF Segment
VBCH•
GROW
US Global Investors Sees 15% AUM Gain, 31% Revenue Growth and $2.6M Profit
GROW•
Sources
F